ALung Technologies has announced its plans to begin US clinical trial testing after the FDA awarded the medical device firm Expedited Pathway Access for its artificial lung technology. The device, HemoLung Respiratory Assist System, was launched in 2013 outside of the United States, and is able to remove carbon dioxide from and deliver oxygen to a patient’s blood. This device may decrease the amount of patients intubated during in and out-patient treatment. Read the full article here.